Search results
Results from the WOW.Com Content Network
On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for sustained long-term growth and innovations in structural heart therapies.
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
In the quarter ended June 30, Edwards' revenue rose 11% to $1.53 billion, above estimates of $1.50 billion. Excluding items, it made a profit of 66 cents per share, compared with estimates of 65 ...
Edwards on Thursday forecast 2024 TAVR sales in the range of $4.0 billion to $4.3 billion, compared with analysts' estimate of $4.23 billion. Edwards Lifesciences to spin off critical care unit to ...
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BRUSSELS (Reuters) -Edwards Lifesciences is working with EU antitrust regulators after they raided one of its facilities in an EU country a week ago, the U.S. medical device maker said on Tuesday.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us